Global Burden of RSV Profiled in Children Aged 0 to 60 Months in 2019
Respiratory syncytial virus (RSV) infection contributes to substantial morbidity and mortality worldwide in children aged 0 to 60 months.
Respiratory syncytial virus (RSV) infection contributes to substantial morbidity and mortality worldwide in children aged 0 to 60 months.
Researchers compared the effect of Gram stain-guided antibiotics with guideline-based antibiotics for the treatment of patients with ventilator-associated pneumonia.
In this meta-analysis, researchers assessed the relationship between 4 infectious bacteria and the risk for ischemic stroke.
Can long-COVID lung diseases be better understood and classified via analysis of abnormalities seen on transbronchial lung cryobiopsies?
Can the Lung Clearance Index, which uses the multiple breath washout test, be used in preschool children to detect lung impairment from primary ciliary dyskinesia?
A bivalent RSV prefusion F protein-based vaccine given during pregnancy elicits neutralizing antibody responses.
How often do survivors of severe COVID-19 pulmonary infection experience long-term exercise capacity limitation, and what factors are associated with this condition?
Consensus definitions for chronic pulmonary aspergillosis treatment outcomes, developed by a panel of international experts convened by CPAnet, were recently published.
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
Azithromycin therapy during acute severe respiratory syncytial virus bronchiolitis does not reduce recurrent wheeze over two to four years.